AIM ImmunoTech Inc. will present at the Webull Corporate Connect Webinar Series, a virtual event scheduled for June 24-25, 2026. Chief Executive Officer Thomas Equels will represent the company during the session, providing insights into its operations and strategic focus.

The presentation is set to take place on Wednesday, June 24, 2026, from 2:40 PM to 3:00 PM ET. Interested participants can register for the webinar through the official link provided by the organizers.

Presentation Details

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen (rintatolimod). The product is intended for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

AIM ImmunoTech Inc. has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses. The company intends to use the net proceeds for the manufacture of clinical drug supply, current and planned Phase 3 clinical trial activities, and working capital purposes. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

Offering Details

The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions. In the registered direct offering, the company will issue and sell 2,554,119 shares of common stock, par value $0.001, at a purchase price of $0.5189 per share. In a concurrent private placement, the company will issue and sell an aggregate of 2,554,119 unregistered shares of Common Stock at the same purchase price.

Warrant Terms

As part of the private placement, the company will issue unregistered Class J warrants to purchase up to 10,216,476 shares of Common Stock. The Class J Warrants will have an exercise price of $0.5189 per share, will be exercisable subject to stockholder approval, and will expire five years from the initial exercise date.

Regulatory Compliance

The registered shares are being offered and sold pursuant to a prospectus supplement to be filed with the Securities and Exchange Commission (SEC) in connection with a takedown from the company's shelf registration statement on Form S-3 (File No. 333-286319), which was declared effective by the SEC on July 3, 2025. The unregistered shares and Class J Warrants will be issued in a concurrent private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.